Thursday 16 October, 2025
Objectives: : Death from chlorpyrifos (CPF) poisoning, a common organophosphorus (OP) pesticide is an increasingly worrying problem in Sri Lanka. However, inaccurate…
Read morePoster: Other Drug/Disease Modelling
From Behaviour to Target: Evaluating the putative correlation between clinical pain scales and biomarkers.
Thursday 16 October, 2025
Objectives: Pain response in clinical trials relies on the use of clinical scales of pain intensity and relief. In contrast…
Read moreMechanistic Model to Characterize and Predict Fecal Excretion of Ciprofloxacin Resistant Enterobacteria with Various Dosage Regimens
Thursday 16 October, 2025
Objectives: Environmental dissemination of antibiotic resistant enterobacteria (EB) via fecal excretion upon fluoroquinolone (FQ) treatment is a major public health…
Read morePopulation pharmacokinetics and pharmacodynamics of benralizumab in healthy volunteers and asthma patients
Thursday 16 October, 2025
Objectives: To characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of benralizumab, an afucosylated human IgG1 monoclonal antibody direct against interleukin-5…
Read morePopulation pharmacokinetics and pharmacodynamics of mavrilimumab in rheumatoid arthritis patients
Thursday 16 October, 2025
Objectives: Mavrilimumab, a fully-human monoclonal antibody targeting the granulocyte-macrophase colony stimulating factor (GM-CSF) receptor α, demonstrated promising efficacy results in…
Read moreA mechanistic PK/PD model to predict the pharmacological depletion of serum amyloid P component in healthy volunteers
Thursday 16 October, 2025
Introduction/Objectives: Amyloidosis is a rare fatal disease caused by progressive extracellular deposition of amyloid fibrils which damage tissue structure and function[1]….
Read moreCharacterization of binding between OSM and mAb in RA patient study: an extension to TMDD models
Thursday 16 October, 2025
Objectives: A humanised IgG1 monoclonal antibody (mAb) against human Oncostatin M (OSM) is being developed for the treatment of rheumatoid…
Read moreA model predicting expected infliximab serum concentrations using only dose and time since last infusion
Thursday 16 October, 2025
Objectives: Infliximab, an anti-TNF-α antibody, has profoundly modified the treatment of several inflammatory diseases but its pharmacokinetics (PK) is highly…
Read moreAdalimumab pharmacokinetics and concentration-effect relationship in rheumatoid arthritis
Thursday 16 October, 2025
Objectives: Adalimumab, an anti-TNF-α monoclonal antibody, is effective in active rheumatoid arthritis (RA). Subcutaneous injections of adalimumab lead to highly…
Read moreModelization of bevacizumab effect on number of episodes of epistaxis in Hereditary Haemorrhagic Telangiectasia (HHT)
Thursday 16 October, 2025
Context: Hereditary Haemorrhagic Telangiectasia (HHT) is a genetic disorder of the blood vessels, which affects approximately 1 in 5,000 people….
Read more